Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Visx' Star

This article was originally published in The Gray Sheet

Executive Summary

Visx' Star: FDA files premarket approval application supplement for use of the excimer laser for treatment of moderate-to-severe myopia between -6 diopters and -12 diopters with up to -4.00 diopters of concomitant myopic astigmatism, the company says. The supplement has been granted expedited review status, Visx notes. The system is currently marketed for treatment of myopia of -1 to -6 diopters with concomitant myopic astigmatism of -0.75 to -0.4 diopters. The laser requires a "simple software change" to be able to treat the patients covered in the new supplement, the firm states. No additional hardware or disposables are required...

You may also be interested in...



Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

Industry Asks If Small Business Loan Relief Applies To Companies With Equity Investors

A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

UsernamePublicRestriction

Register

MT008775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel